NCT01613690View on ClinicalTrials.gov

Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Renal Impairment
Interventions
DRUG

NVA237

NVA237 is administered via a BREEZHALER device

Trial Locations (1)

Unknown

Novartis Investigative Site, Moscow

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY